IRESSA 250 MG

GEFITINIB

Reimbursement base

21.036,00 MAD

Active substance

GEFITINIB

What is this medicine?

Gefitinib is a tyrosine kinase inhibitor used for the first-line treatment of specific metastatic non-small cell lung cancer.

Verified summary

GEFITINIB, COMPRIME PELLICULE, 250 MG, 1 BOITE 30 COMPRIME PELLICULE

Common uses

First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

Class

Tyrosine kinase inhibitor

Hospital price

21.036,00 MAD

Strength

250 MG

Form

COMPRIME PELLICULE

Presentation

1 BOITE 30 COMPRIME PELLICULE

Type

This information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.

Price history

Reference price recorded since 2017-12-18: 0,00 MAD

Available presentations and strengths

IRESSA

250 MG · BOITE DE 30

9,36 MAD

IRESSA 250 MG

250 MG · Boite de 30

9.355,00 MAD

Medicines with the same active substance

GEFLA

250 MG · BOITE DE 30 COMPRIMES PELLICULES

9,36 MAD

GEFTINAT

250 MG · BOITE DE 30 COMPRIMES PELLICULES

9,36 MAD

GEFLA 250 MG

250 MG · Boite de 30

9.355,00 MAD

GEFTINAT 250 MG

250 MG · Boite de 30

9.399,00 MAD